The c.156-157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal

Breast Cancer Research and Treatment

Volumn 114, Issue 1, 2009, Pages 31-38

  Peixoto, Ana ^a   Santos, Catarina ^a   Rocha, Patrícia ^a   Pinheiro, Manuela ^a   Príncipe, Sofia ^a   Pereira, Deolinda ^a   Rodrigues, Helena ^a   Castro, Fernando ^a   Abreu, Joaquim ^a   Gusmão, Leonor ^b   Amorim, António ^b   Teixeira, Manuel R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Breast cancer; C.156 157insAlu BRCA2 mutation; Hereditary predisposition

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENOMIC DNA; RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PORTUGAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PORTUGAL;

EID: 58849092856     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9978-4     Document Type: Article

References (25)

1. P Tonin O Serova G Lenoir 1995 BRCA1 mutations in Ashkenazi Jewish women Am J Hum Genet 57 189
2. F Durocher P Tonin D Shattuck-Eidens 1996 Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites J Med Genet 33 814 819
3. PN Tonin AM Mes-Masson PA Futreal 1998 Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families Am J Hum Genet 63 1341 1351
4. A Dørum E Hovig C Tropé 1999 Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or1135insA Eur J Cancer 35 779 781
5. T Peelen RS Cornelis M van Vliet 1996 The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1or BRCA2 Eur J Hum Genet 4 225 230
6. A Petrij-Bosch T Peelen M van Vliet 1997 BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients Nat Genet 17 341 345
7. B Górski A Jakubowska T Huzarski 2004 A high proportion of founder BRCA1 mutations in Polish breast cancer families Int J Cancer 110 683 686
8. I Konstantopoulou T Rampias A Ladopoulou 2008 Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients Breast Cancer Res Treat 107 431 441
9. Anagnostopoulos T, Pertesi M, Konstantopoulou I et al (2007) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat. doi: 10.1007/s10549-007-9729-y
10. T Rafnar KR Benediktsdottir BJ Eldon 2004 BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study Eur J Cancer 40 2788 2793
11. B Campos O Díez F Odefrey 2003 Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain Hum Mutat 21 452
12. O Díez A Osorio M Durán 2003 Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects Hum Mutat 22 301 312
13. A Bergman Z Einbeigi U Olofsson 2001 The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation Eur J Hum Genet 9 787 793
14. A Peixoto N Salgueiro C Santos 2006 BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families Fam Cancer 5 379 387
15. E Teugels S De Brakeleer G Goelen 2005 De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes Hum Mutat 26 284
16. PM Machado RD Brandão BM Cavaco 2007 Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes J Clin Oncol 25 2027 2034
17. O Díez S Gutiérrez-Enríquez T Ramón y Cajal 2007 Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families J Clin Oncol 25 5035 5036
18. G Parmigiani D Berry O Aguilar 1998 Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 Am J Hum Genet 62 145 158
19. AH van der Hout AM van den Ouweland RB van der Luijt 2006 A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting Hum Mutat 27 654 666
20. K Claes B Poppe I Coene 2004 BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families Br J Cancer 90 1244 1251
21. M Perkowska I BroZek B Wysocka 2003 BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland Hum Mutat 21 553 554
22. HA Shih FJ Couch KL Nathanson 2002 BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic J Clin Oncol 20 994 999
23. T Judkins BC Hendrickson AM Deffenbaugh 2005 Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1 Mutat Res 573 168 179
24. DJ Rowold RJ Herrera 2000 Alu elements and the human genome Genetica 108 57 72
25. KK Oros G Leblanc SL Arcand 2006 Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families BMC Med Genet 7 23